1-[5-(4-Benzenesulfonyl-5-oxy-furazan-3-yloxymethyl)-4-hydroxy-tetrahydro-furan-2-yl]-1H-pyrimidine-2,4-dione

ID: ALA3144455

Chembl Id: CHEMBL3144455

PubChem CID: 11487797

Max Phase: Preclinical

Molecular Formula: C17H16N4O9S

Molecular Weight: 452.40

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=c1ccn([C@H]2C[C@H](O)[C@@H](COc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)O2)c(=O)[nH]1

Standard InChI:  InChI=1S/C17H16N4O9S/c22-11-8-14(20-7-6-13(23)18-17(20)24)29-12(11)9-28-15-16(21(25)30-19-15)31(26,27)10-4-2-1-3-5-10/h1-7,11-12,14,22H,8-9H2,(H,18,23,24)/t11-,12+,14+/m0/s1

Standard InChI Key:  FHOSMOKEYPJCQK-OUCADQQQSA-N

Associated Targets(Human)

143B (353 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hs-578T (29457 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

KBALB cell line (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EMT6 (738 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 452.40Molecular Weight (Monoisotopic): 452.0638AlogP: -1.28#Rotatable Bonds: 6
Polar Surface Area: 180.66Molecular Species: NEUTRALHBA: 11HBD: 2
#RO5 Violations: 1HBA (Lipinski): 13HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 9.71CX Basic pKa: CX LogP: -0.74CX LogD: -0.74
Aromatic Rings: 3Heavy Atoms: 31QED Weighted: 0.43Np Likeness Score: -0.07

References

1. Moharram S, Zhou A, Wiebe LI, Knaus EE..  (2004)  Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.,  47  (7): [PMID:15027876] [10.1021/jm030544m]

Source